

## Connecting via Winsock to STN

## STN Search

9/19/03

B. B. B.

Welcome to STN International! Enter x:x

LOGINID: ssspta1200rxh

**PASSWORD :**

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the present  
NEWS 4 Jul 15 Data from 1960-1976 added to RDISCLOSURE  
NEWS 5 Jul 21 Identification of STN records implemented  
NEWS 6 Jul 21 Polymer class term count added to REGISTRY  
NEWS 7 Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available  
NEWS 8 AUG 05 New pricing for EUROPATFULL and PCTFULL effective August 1, 2003  
NEWS 9 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN  
NEWS 10 AUG 15 PATDPAFULL: one FREE connect hour, per account, in September 2003  
NEWS 11 AUG 15 PCTGEN: one FREE connect hour, per account, in September 2003  
NEWS 12 AUG 15 RDISCLOSURE: one FREE connect hour, per account, in September 2003  
NEWS 13 AUG 15 TEMA: one FREE connect hour, per account, in September 2003  
NEWS 14 AUG 18 Data available for download as a PDF in RDISCLOSURE  
NEWS 15 AUG 18 Simultaneous left and right truncation added to PASCAL  
NEWS 16 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation  
NEWS 17 AUG 18 Simultaneous left and right truncation added to ANABSTR  
  
NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:33:56 ON 19 SEP 2003

=> fil uspatful

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'USPATFULL' ENTERED AT 13:35:33 ON 19 SEP 2003  
 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 18 Sep 2003 (20030918/PD)  
 FILE LAST UPDATED: 18 Sep 2003 (20030918/ED)  
 HIGHEST GRANTED PATENT NUMBER: US6622308  
 HIGHEST APPLICATION PUBLICATION NUMBER: US2003177560  
 CA INDEXING IS CURRENT THROUGH 18 Sep 2003 (20030918/UPCA)  
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 18 Sep 2003 (20030918/PD)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2003  
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<  
 >>> original, i.e., the earliest published granted patents or <<<  
 >>> applications. USPAT2 contains full text of the latest US <<<  
 >>> publications, starting in 2001, for the inventions covered in <<<  
 >>> USPATFULL. A USPATFULL record contains not only the original <<<  
 >>> published document but also a list of any subsequent <<<  
 >>> publications. The publication number, patent kind code, and <<<  
 >>> publication date for all the US publications for an invention <<<  
 >>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
 >>> records and may be searched in standard search fields, e.g., /PN, <<<  
 >>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
 >>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
 >>> enter this cluster. <<<

>>>  
 >>> Use USPATALL when searching terms such as patent assignees, <<<  
 >>> classifications, or claims, that may potentially change from <<<  
 >>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s cortisol/ti,ab
      13 CORTISOL/TI
      57 CORTISOL/AB
L1      57 CORTISOL/TI,AB

=> s (antagonist or antagonists)/ti,ab
      655 ANTAGONIST/TI
      2584 ANTAGONIST/AB
      2794 ANTAGONISTS/TI
      5687 ANTAGONISTS/AB
L2      8874 (ANTAGONIST OR ANTAGONISTS)/TI,AB

=> s l1 and l2
L3          10 L1 AND L2

=> d 13 1-10

L3      ANSWER 1 OF 10 USPATFULL ON STN
AN      2003:246905 USPATFULL
TI      Methods of treating mild cognitive impairment using a
          glucocorticoid-specific receptor antagonist
IN      Schatzberg, Alan F., Los Altos, CA, United States
          Belanoff, Joseph K., Woodside, CA, United States
PA      Corcept Therapeutics, Inc., Menlo Park, CA, United States (U.S.
          corporation)
```

PI US 6620802 B1 20030916  
AI US 2000-717703 20001120 (9)  
PRAI US 1999-167432P 19991123 (60)  
DT Utility  
FS GRANTED  
LN.CNT 1210  
INCL INCLM: 514/178.000  
NCL NCLM: 514/178.000  
IC [7]  
ICM: A61K031-56  
EXF 514/178

L3 ANSWER 2 OF 10 USPATFULL on STN  
AN 2003:93613 USPATFULL  
TI Methods for inhibiting cognitive deterioration in adults with down's syndrome  
IN Belanoff, Joseph K., Woodside, CA, UNITED STATES  
PA Corcept Therapeutics, Inc. (U.S. corporation)  
PI US 2003064974 A1 20030403  
AI US 2002-230575 A1 20020828 (10)  
PRAI US 2001-316653P 20010831 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1295  
INCL INCLM: 514/179.000  
NCL NCLM: 514/179.000  
IC [7]  
ICM: A61K031-573

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 10 USPATFULL on STN  
AN 2003:38155 USPATFULL  
TI Methods for preventing antipsychotic-induced weight gain  
IN Belanoff, Joseph K., Woodside, CA, UNITED STATES  
Schatzberg, Alan F., Los Altos, CA, UNITED STATES  
PA Corcept Therapeutics, Inc. (U.S. corporation)  
PI US 2003027802 A1 20030206  
AI US 2002-201356 A1 20020722 (10)  
PRAI US 2001-307693P 20010723 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1123  
INCL INCLM: 514/171.000  
INCLS: 514/220.000; 514/259.410; 514/419.000  
NCL NCLM: 514/171.000  
NCLS: 514/220.000; 514/259.410; 514/419.000  
IC [7]  
ICM: A61K031-56  
ICS: A61K031-551; A61K031-405; A61K031-519

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 10 USPATFULL on STN  
AN 2002:301607 USPATFULL  
TI Methods for treating stress disorders using glucocorticoid receptor-specific antagonists  
IN Belanoff, Joseph K., Woodside, CA, UNITED STATES  
PA Corcept Therapeutics, Inc. (U.S. corporation)  
PI US 2002169152 A1 20021114  
AI US 2002-102448 A1 20020319 (10)  
PRAI US 2001-278523P 20010323 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1140  
INCL INCLM: 514/179.000

NCL NCLM: 514/179.000  
IC [7]  
ICM: A61K031-57  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 10 USPATFULL on STN  
AN 2002:106303 USPATFULL  
TI Compositions for delivery of a **cortisol antagonist**  
IN Marin, Per, Vastra Frolunda, SWEDEN  
Landh, Tomas, Lund, SWEDEN  
Osthholm, Ivan, Goteborg, SWEDEN  
PA CORTENDO AB. (non-U.S. corporation)  
PI US 2002055512 A1 20020509  
AI US 2001-809979 A1 20010316 (9)  
RLI Continuation-in-part of Ser. No. US 2000-691688, filed on 18 Oct 2000,  
UNKNOWN  
PRAI GB 2000-1449 20000121  
DT Utility  
FS APPLICATION  
LN.CNT 1462  
INCL INCLM: 514/254.070  
NCL NCLM: 514/254.070  
IC [7]  
ICM: A61K031-496  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 10 USPATFULL on STN  
AN 2002:75422 USPATFULL  
TI Methods for treating dementia  
IN Schatzberg, Alan F., Los Altos, CA, United States  
Belanoff, Joseph K., Woodside, CA, United States  
PA The Board of Trustees of the Leland Stanford Junior University,  
Stanford, CA, United States (U.S. corporation)  
PI US 6369046 B1 20020409  
AI US 1999-246780 19990204 (9)  
PRAI US 1998-85703P 19980515 (60)  
DT Utility  
FS GRANTED  
LN.CNT 1433  
INCL INCLM: 514/167.000  
INCLS: 514/169.000  
NCL NCLM: 514/167.000  
NCLS: 514/169.000  
IC [7]  
ICM: A61K031-59  
ICS: A61K031-56  
EXF 514/167; 514/169  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 10 USPATFULL on STN  
AN 2002:69990 USPATFULL  
TI 4-aza steroids  
IN Pribish, James R., Sharonville, OH, United States  
Gates, Cynthia A., Fairfield, OH, United States  
Weintraub, Philip M., Cincinnati, OH, United States  
PA Aventis Pharmaceuticals Inc., Bridgewater, NJ, United States (U.S.  
corporation)  
PI US 6365597 B1 20020402  
AI US 1997-798258 19970211 (8)  
PRAI US 1996-46877P 19960214 (60)  
DT Utility  
FS GRANTED  
LN.CNT 2915  
INCL INCLM: 514/284.000

NCL INCLS: 546/077.000; 546/078.000  
NCLM: 514/284.000  
NCLS: 546/077.000; 546/078.000  
IC [7]  
ICM: A61K031-44  
ICS: C07D221-18; C07D221-22; A61P017-10  
EXF 546/77; 546/78; 514/284  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 10 USPATFULL on STN  
AN 2002:63894 USPATFULL  
TI Methods for treating psychosis associated with cocaine addiction with glucocorticoid receptor antagonists  
IN Schatzberg, Alan F., Los Altos, CA, United States  
Belanoff, Joseph K., Cupertino, CA, United States  
PA The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)  
PI US 6362173 B1 20020326  
AI US 2000-639377 20000815 (9)  
RLI Continuation of Ser. No. US 1999-244457, filed on 4 Feb 1999, now patented, Pat. No. US 6150349 Continuation of Ser. No. WO 1998-US20906, filed on 5 Oct 1998  
PRAI US 1997-60973P 19971006 (60)  
DT Utility  
FS GRANTED  
LN.CNT 1515  
INCL INCLM: 514/179.000  
NCL NCLM: 514/179.000  
IC [7]  
ICM: A61K031-56  
EXF 514/179  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 10 USPATFULL on STN  
AN 2002:32724 USPATFULL  
TI 20-Fluoro-17(20)-vinyl steroids  
IN Peet, Norton P., North Andover, MA, UNITED STATES  
Weintraub, Philip M., Warren, NJ, UNITED STATES  
Berkhart, Joseph P., Plainfield, IN, UNITED STATES  
Gates, Cynthia A., Cambridge, MA, UNITED STATES  
PI US 2002019548 A1 20020214  
US 6413951 B2 20020702  
AI US 2001-886818 A1 20010621 (9)  
PRAI GB 2001-1523 20010119  
US 2001-290881P 20010514 (60)  
US 2000-214561P 20000627 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 2407  
INCL INCLM: 552/515.000  
INCLS: 552/606.000; 514/177.000; 514/182.000  
NCL NCLM: 514/177.000  
NCLS: 514/182.000; 552/515.000; 552/530.000; 552/532.000  
IC [7]  
ICM: C07J041-00  
ICS: A61K031-56; C07J007-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 10 USPATFULL on STN  
AN 2000:157400 USPATFULL  
TI Methods for treating psychosis associated with glucocorticoid related dysfunction  
IN Schatzberg, Alan F., Los Altos, CA, United States  
Belanoff, Joseph K., Cupertino, CA, United States

PA The Board of Trustees of the Leland Stanford Junior University, Palo  
Alto, CA, United States (U.S. corporation)  
PI US 6150349 20001121  
AI US 1999-244457 19990204 (9)  
RLI Continuation of Ser. No. WO 1998-US20906, filed on 5 Oct 1998  
PRAI US 1997-60973P 19971006 (60)  
DT Utility  
FS Granted  
LN.CNT 1515  
INCL INCLM: 514/179.000  
NCL NCLM: 514/179.000  
IC [7]  
ICM: A61K031-56  
EXF 514/179  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 6 hit

L3 ANSWER 6 OF 10 USPATFULL on STN  
AB This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of **cortisol** to its receptors can be used in methods for treating dementia. Mifepristone, a potent glucocorticoid receptor **antagonist**, can be used in these methods. The invention also provides a kit for treating dementia in a human including a glucocorticoid receptor **antagonist** and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor **antagonist**.

=> s (corisol(2a) (antagonist or antagonists))  
4 CORISOL  
29439 ANTAGONIST  
34696 ANTAGONISTS  
L4 0 (CORISOL(2A) (ANTAGONIST OR ANTAGONISTS))

=> s (cortisol(2a) (antagonist or antagonists))  
2763 CORTISOL  
29439 ANTAGONIST  
34696 ANTAGONISTS  
L5 12 (CORTISOL(2A) (ANTAGONIST OR ANTAGONISTS))

=> d 15 1-12

L5 ANSWER 1 OF 12 USPATFULL on STN  
AN 2003:246905 USPATFULL  
TI Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist  
IN Schatzberg, Alan F., Los Altos, CA, United States  
Belanoff, Joseph K., Woodside, CA, United States  
PA Corcept Therapeutics, Inc., Menlo Park, CA, United States (U.S. corporation)  
PI US 6620802 B1 20030916  
AI US 2000-717703 20001120 (9)  
PRAI US 1999-167432P 19991123 (60)  
DT Utility  
FS GRANTED  
LN.CNT 1210  
INCL INCLM: 514/178.000  
NCL NCLM: 514/178.000  
IC [7]  
ICM: A61K031-56  
EXF 514/178

L5 ANSWER 2 OF 12 USPATFULL on STN  
AN 2003:93613 USPATFULL  
TI Methods for inhibiting cognitive deterioration in adults with down's syndrome  
IN Belanoff, Joseph K., Woodside, CA, UNITED STATES  
PA Corcept Therapeutics, Inc. (U.S. corporation)  
PI US 2003064974 A1 20030403  
AI US 2002-230575 A1 20020828 (10)  
PRAI US 2001-316653P 20010831 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1295  
INCL INCLM: 514/179.000  
NCL NCLM: 514/179.000  
IC [7]  
ICM: A61K031-573  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 12 USPATFULL on STN  
AN 2003:38155 USPATFULL  
TI Methods for preventing antipsychotic-induced weight gain  
IN Belanoff, Joseph K., Woodside, CA, UNITED STATES  
Schatzberg, Alan F., Los Altos, CA, UNITED STATES  
PA Corcept Therapeutics, Inc. (U.S. corporation)  
PI US 2003027802 A1 20030206  
AI US 2002-201356 A1 20020722 (10)  
PRAI US 2001-307693P 20010723 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1123  
INCL INCLM: 514/171.000  
INCLS: 514/220.000; 514/259.410; 514/419.000  
NCL NCLM: 514/171.000  
NCLS: 514/220.000; 514/259.410; 514/419.000  
IC [7]  
ICM: A61K031-56  
ICS: A61K031-551; A61K031-405; A61K031-519  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 12 USPATFULL on STN  
AN 2003:17457 USPATFULL  
TI Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome  
IN Marin, Per, Goteborg, SWEDEN  
PI US 2003013209 A1 20030116  
AI US 2002-179904 A1 20020625 (10)  
RLI Division of Ser. No. US 1998-952638, filed on 26 Feb 1998, GRANTED, Pat. No. US 6410339  
DT Utility  
FS APPLICATION  
LN.CNT 196  
INCL INCLM: 436/518.000  
INCLS: 436/071.000; 436/500.000; 435/003.000; 435/004.000  
NCL NCLM: 436/518.000  
NCLS: 436/071.000; 436/500.000; 435/003.000; 435/004.000  
IC [7]  
ICM: G01N033-543  
ICS: G01N033-92; C12Q003-00; C12Q001-00; G01N033-53  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 12 USPATFULL on STN  
AN 2002:301607 USPATFULL  
TI Methods for treating stress disorders using glucocorticoid

receptor-specific antagonists  
IN Belanoff, Joseph K., Woodside, CA, UNITED STATES  
PA Corcept Therapeutics, Inc. (U.S. corporation)  
PI US 2002169152 A1 20021114  
AI US 2002-102448 A1 20020319 (10)  
PRAI US 2001-278523P 20010323 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1140  
INCL INCLM: 514/179.000  
NCL NCLM: 514/179.000  
IC [7]  
ICM: A61K031-57  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 12 USPATFULL on STN  
AN 2002:106303 USPATFULL  
TI Compositions for delivery of a **cortisol antagonist**  
IN Marin, Per, Vastra Frolunda, SWEDEN  
Landh, Tomas, Lund, SWEDEN  
Osthholm, Ivan, Goteborg, SWEDEN  
PA CORTENDO AB. (non-U.S. corporation)  
PI US 2002055512 A1 20020509  
AI US 2001-809979 A1 20010316 (9)  
RLI Continuation-in-part of Ser. No. US 2000-691688, filed on 18 Oct 2000,  
UNKNOWN  
PRAI GB 2000-1449 20000121  
DT Utility  
FS APPLICATION  
LN.CNT 1462  
INCL INCLM: 514/254.070  
NCL NCLM: 514/254.070  
IC [7]  
ICM: A61K031-496  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 12 USPATFULL on STN  
AN 2002:75422 USPATFULL  
TI Methods for treating dementia  
IN Schatzberg, Alan F., Los Altos, CA, United States  
Belanoff, Joseph K., Woodside, CA, United States  
PA The Board of Trustees of the Leland Stanford Junior University,  
Stanford, CA, United States (U.S. corporation)  
PI US 6369046 B1 20020409  
AI US 1999-246780 19990204 (9)  
PRAI US 1998-85703P 19980515 (60)  
DT Utility  
FS GRANTED  
LN.CNT 1433  
INCL INCLM: 514/167.000  
INCLS: 514/169.000  
NCL NCLM: 514/167.000  
NCLS: 514/169.000  
IC [7]  
ICM: A61K031-59  
ICS: A61K031-56  
EXF 514/167; 514/169  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 12 USPATFULL on STN  
AN 2001:118224 USPATFULL  
TI Nuclear receptor ligands and ligand binding domains  
IN Scanlan, Thomas S., San Francisco, CA, United States  
Baxter, John D., San Francisco, CA, United States

Fletterick, Robert J., San Francisco, CA, United States  
Wagner, Richard L., San Francisco, CA, United States  
Kushner, Peter J., San Francisco, CA, United States  
Apriletti, James J., Berkeley, CA, United States  
West, Brian L., San Francisco, CA, United States  
Shiau, Andrew K., San Francisco, CA, United States  
PA Regents of the University of California, Oakland, CA, United States  
(U.S. corporation)  
PI US 6266622 B1 20010724  
AI US 1997-980115 19971126 (8)  
RLI Continuation-in-part of Ser. No. US 1996-764870, filed on 13 Dec 1996  
PRAI US 1995-8540P 19951213 (60)  
US 1995-8543P 19951213 (60)  
US 1995-8606P 19951214 (60)  
DT Utility  
FS GRANTED  
LN.CNT 18910  
INCL INCLM: 702/022.000  
INCLS: 702/019.000; 702/020.000; 530/350.000  
NCL NCLM: 702/022.000  
NCLS: 530/350.000; 702/019.000; 702/020.000  
IC [7]  
ICM: G06F019-00  
ICS: G06F017-00; C07G014-00  
EXF 702/19; 702/21; 702/22; 530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 12 USPATFULL on STN  
AN 2001:76593 USPATFULL  
TI Nuclear receptor ligands and ligand binding domains  
IN Scanlan, Thomas S., 2525 Moraga St., San Francisco, CA, United States  
94122  
Baxter, John D., 131 San Pablo Ave., San Francisco, CA, United States  
94127  
Fletterick, Robert J., 15 Christopher Ave., San Francisco, CA, United  
States 94131  
Wagner, Richard L., 1704 Waller St., San Francisco, CA, United States  
94117  
Kushner, Peter J., 1362 6th Ave., San Francisco, CA, United States  
94122  
Apriletti, James, 11 Virginia Gardens, Berkeley, CA, United States  
94702  
West, Brian, 142 Anderson St., San Francisco, CA, United States 94110  
Shiau, Andrew K., 34 Hugo St. #3, San Francisco, CA, United States  
94122  
PI US 6236946 B1 20010522  
AI US 1996-764870 19961213 (8)  
PRAI US 1995-8540P 19951213 (60)  
US 1995-8543P 19951213 (60)  
US 1995-8606P 19951214 (60)  
DT Utility  
FS Granted  
LN.CNT 3042  
INCL INCLM: 702/022.000  
INCLS: 702/019.000; 702/020.000; 530/350.000  
NCL NCLM: 702/022.000  
NCLS: 530/350.000; 702/019.000; 702/020.000  
IC [7]  
ICM: G06F019-00  
ICS: G06F017-00; C07K014-00  
EXF 702/14; 702/21; 702/22; 530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 12 USPATFULL on STN

AN 1999:75623 USPATFULL  
TI Use of pyruvate and anti-cortisol compounds in a method for enhancing physical endurance and athletic endurance in a mammal  
IN Beale, Paxton K., 1801 Bush St., Suite 300, San Francisco, CA, United States 94109  
PI US 5919767 19990706  
AI US 1998-27522 19980223 (9)  
RLI Division of Ser. No. US 1996-686820, filed on 26 Jul 1996, now patented, Pat. No. US 5756469  
DT Utility  
FS Granted  
LN.CNT 484  
INCL INCLM: 514/023.000  
INCLS: 514/053.000; 514/078.000  
NCL NCLM: 514/023.000  
NCLS: 514/053.000; 514/078.000  
IC [6]  
ICM: A61K031-70  
ICS: A61K031-715; A61K031-685  
EXF 514/23; 514/53; 514/78  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 12 USPATFULL on STN  
AN 1999:19138 USPATFULL  
TI Low dosage treatment for cocaine craving and withdrawal  
IN Goeders, Nicholas E., Shreveport, LA, United States  
PA Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA, United States (U.S. corporation)  
PI US 5869474 19990209  
AI US 1997-857376 19970516 (8)  
DT Utility  
FS Granted  
LN.CNT 732  
INCL INCLM: 514/171.000  
INCLS: 514/252.000; 514/327.000; 514/382.000; 514/396.000; 514/812.000  
NCL NCLM: 514/171.000  
NCLS: 514/254.070; 514/327.000; 514/382.000; 514/396.000; 514/812.000  
IC [6]  
ICM: A61K031-50  
ICS: A61K031-56; A61K031-495  
EXF 514/171; 514/252; 514/327; 514/382; 514/396; 514/812  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 12 USPATFULL on STN  
AN 1998:57893 USPATFULL  
TI Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal  
IN Beale, Paxton K., 1801 Bush St., Suite 300, San Francisco, CA, United States 94109  
PI US 5756469 19980526  
AI US 1996-686820 19960726 (8)  
DT Utility  
FS Granted  
LN.CNT 542  
INCL INCLM: 514/023.000  
INCLS: 514/053.000; 514/078.000  
NCL NCLM: 514/023.000  
NCLS: 514/053.000; 514/078.000  
IC [6]  
ICM: A61K031-70  
ICS: A61K031-715; A61K031-685  
EXF 514/23; 514/53; 514/78  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> fil reg			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
	ENTRY	SESSION	
FULL ESTIMATED COST	31.67	32.30	

FILE 'REGISTRY' ENTERED AT 13:40:43 ON 19 SEP 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2003 HIGHEST RN 588668-76-2  
 DICTIONARY FILE UPDATES: 18 SEP 2003 HIGHEST RN 588668-76-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
 PROPERTIES for more information. See STNote 27, Searching Properties  
 in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s fungoral/cn  
 L6 1 FUNGORAL/CN

=> d 16

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 65277-42-1 REGISTRY  
 CN Piperazine, 1-acetyl-4-[4-[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, rel- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Piperazine, 1-acetyl-4-[4-[(2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, cis-

OTHER NAMES:

CN (.-.)-Ketoconazole

CN Fungarest

CN Fungoral

CN Ketoconazole

CN Ketoderm

CN Ketoisdin

CN Nizoral

CN Nizral

CN Orifungal M

CN Panfungol

CN R 41400

FS STEREOSEARCH

DR 72093-26-6


MF C26 H28 Cl2 N4 O4

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*,  
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT,  
 CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU,  
 DIOGENES, DRUGPAT, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,  
 MRCK\*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS\*, SPECINFO,  
 SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU

(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, WHO  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2412 REFERENCES IN FILE CA (1937 TO DATE)  
40 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
2416 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> fil.uspatfull	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	6.30	38.60

FILE 'USPATFULL' ENTERED AT 13:40:59 ON 19 SEP 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 18 Sep 2003 (20030918/PD)  
FILE LAST UPDATED: 18 Sep 2003 (20030918/ED)  
HIGHEST GRANTED PATENT NUMBER: US6622308  
HIGHEST APPLICATION PUBLICATION NUMBER: US2003177560  
CA INDEXING IS CURRENT THROUGH 18 Sep 2003 (20030918/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 18 Sep 2003 (20030918/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2003  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<  
>>> original, i.e., the earliest published granted patents or <<<  
>>> applications. USPAT2 contains full text of the latest US <<<  
>>> publications, starting in 2001, for the inventions covered in <<<  
>>> USPATFULL. A USPATFULL record contains not only the original <<<  
>>> published document but also a list of any subsequent <<<  
>>> publications. The publication number, patent kind code, and <<<  
>>> publication date for all the US publications for an invention <<<  
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
>>> records and may be searched in standard search fields, e.g., /PN, <<<  
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
>>> enter this cluster. <<<

>>> Use USPATALL when searching terms such as patent assignees, <<<  
>>> classifications, or claims, that may potentially change from <<<  
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> d his

(FILE 'HOME' ENTERED AT 13:33:56 ON 19 SEP 2003)

FILE 'USPATFULL' ENTERED AT 13:35:33 ON 19 SEP 2003

L1 57 S CORTISOL/TI,AB  
L2 8874 S (ANTAGONIST OR ANTAGONISTS)/TI,AB  
L3 10 S L1 AND L2  
L4 0 S (CORTISOL(2A) (ANTAGONIST OR ANTAGONISTS))  
L5 12 S (CORTISOL(2A) (ANTAGONIST OR ANTAGONISTS))

FILE 'REGISTRY' ENTERED AT 13:40:43 ON 19 SEP 2003

L6 1 S FUNGORAL/CN

FILE 'USPATFULL' ENTERED AT 13:40:59 ON 19 SEP 2003

=> s 16  
L7 402 L6

=> s 17 and cortisol  
2763 CORTISOL  
L8 29 L7 AND CORTISOL

=> d 18 1-29

L8 ANSWER 1 OF 29 USPATFULL on STN  
AN 2003:200796 USPATFULL  
TI Methods for determining steroid responsiveness  
IN Whitehead, Alexander Steven, Wayne, PA, UNITED STATES  
PI US 2003138781 A1 20030724  
AI US 2002-45360 A1 20020122 (10)  
DT Utility  
FS APPLICATION  
LN.CNT 1661  
INCL INCLM: 435/006.000  
INCLS: 702/020.000  
NCL NCLM: 435/006.000  
NCLS: 702/020.000  
IC [7]  
ICM: C12Q001-68  
ICS: G06F019-00; G01N033-48; G01N033-50  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 29 USPATFULL on STN  
AN 2003:188461 USPATFULL  
TI Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes  
IN Marfat, Anthony, UNITED STATES  
McKechney, Michael William, UNITED STATES  
PI US 2003130254 A1 20030710  
AI US 2002-300959 A1 20021120 (10)  
RLI Division of Ser. No. US 2002-62145, filed on 31 Jan 2002, PENDING  
PRAI US 2001-265486P 20010131 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 7168  
INCL INCLM: 514/210.200  
INCLS: 514/227.800; 514/235.500; 514/249.000; 514/248.000; 514/263.200;

514/266.200; 514/256.000; 514/255.050; 514/252.050; 514/365.000;  
514/314.000  
NCL NCLM: 514/210.200  
NCLS: 514/227.800; 514/235.500; 514/249.000; 514/248.000; 514/263.200;  
514/266.200; 514/256.000; 514/255.050; 514/252.050; 514/365.000;  
514/314.000

IC [7]  
ICM: A61K031-541  
ICS: A61K031-5377; A61K031-506; A61K031-52; A61K031-517; A61K031-4709;  
A61K031-427; C07D417-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 29 USPATFULL on STN  
AN 2003:187370 USPATFULL  
TI Use of a polypeptide for treatment of pruritis in animals  
IN Lipton, James M., Woodland Hills, CA, UNITED STATES  
Catania, Anna P., Milan, ITALY  
PI US 2003129156 A1 20030710  
AI US 2001-23287 A1 20011217 (10)  
DT Utility  
FS APPLICATION  
LN.CNT 1612  
INCL INCLM: 424/070.210  
INCLS: 514/018.000; 514/014.000; 514/015.000; 514/016.000  
NCL NCLM: 424/070.210  
NCLS: 514/018.000; 514/014.000; 514/015.000; 514/016.000  
IC [7]  
ICM: A61K038-10  
ICS: A61K038-08; A61K038-05  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 29 USPATFULL on STN  
AN 2002:338241 USPATFULL  
TI Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes  
IN Chambers, Robert J., Mystic, CT, UNITED STATES  
Marfat, Anthony, Mystic, CT, UNITED STATES  
Magee, Thomas V., Mystic, CT, UNITED STATES  
PA Pfizer Inc. (U.S. corporation)  
PI US 2002193612 A1 20021219  
AI US 2002-62813 A1 20020131 (10)  
PRAI US 2001-265492P 20010131 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 7001  
INCL INCLM: 549/200.000  
NCL NCLM: 549/200.000  
IC [7]  
ICM: C07D321-00  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 29 USPATFULL on STN  
AN 2002:228358 USPATFULL  
TI Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives  
useful as inhibitors of PDE4 isozymes  
IN Marfat, Anthony, Mystic, CT, UNITED STATES  
McKechney, Michael William, Fairport, NY, UNITED STATES  
PA Pfizer Inc. (U.S. corporation)  
PI US 2002123520 A1 20020905  
US 6559168 B2 20030506  
AI US 2002-62145 A1 20020131 (10)  
PRAI US 2001-265486P 20010131 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 6963

INCL INCLM: 514/365.000  
INCLS: 514/398.000; 548/188.000; 548/323.100; 514/341.000; 514/342.000;  
546/269.700; 546/272.700  
NCL NCLM: 514/338.000  
NCLS: 514/342.000; 514/369.000; 514/370.000; 546/269.700; 548/188.000;  
548/195.000; 548/196.000

IC [7]  
ICM: A61K031-4439  
ICS: A61K031-426; C07D417-02; C07D043-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 29 USPATFULL on STN  
AN 2002:126742 USPATFULL  
TI Glucocorticoid blocking agents for increasing blood-brain barrier  
permeability  
IN Schatzberg, Alan F., Los Altos, CA, UNITED STATES  
Belanoff, Joseph K., Woodside, CA, UNITED STATES  
Lindley, Steven, Redwood City, CA, UNITED STATES  
PI US 2002065259 A1 20020530  
AI US 2001-942531 A1 20010829 (9)  
PRAI US 2000-229278P 20000830 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 962  
INCL INCLM: 514/179.000  
NCL NCLM: 514/179.000  
IC [7]  
ICM: A61K031-57

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 29 USPATFULL on STN  
AN 2002:106303 USPATFULL  
TI Compositions for delivery of a **cortisol** antagonist  
IN Marin, Per, Vastra Frolunda, SWEDEN  
Landh, Tomas, Lund, SWEDEN  
Osthholm, Ivan, Goteborg, SWEDEN  
PA CORTENDO AB. (non-U.S. corporation)  
PI US 2002055512 A1 20020509  
AI US 2001-809979 A1 20010316 (9)  
RLI Continuation-in-part of Ser. No. US 2000-691688, filed on 18 Oct 2000,  
UNKNOWN  
PRAI GB 2000-1449 20000121  
DT Utility  
FS APPLICATION  
LN.CNT 1462  
INCL INCLM: 514/254.070  
NCL NCLM: 514/254.070  
IC [7]  
ICM: A61K031-496

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 29 USPATFULL on STN  
AN 2002:48049 USPATFULL  
TI Timed-release compression-coated solid composition for oral  
administration  
IN Sawada, Toyohiro, Fujieda-shi, JAPAN  
Sako, Kazuhiro, Yaizu-shi, JAPAN  
Yoshioka, Tatsunobu, Yaizu-shi, JAPAN  
Watanabe, Shunsuke, Fujieda-shi, JAPAN  
PI US 2002028240 A1 20020307  
AI US 2001-834410 A1 20010412 (9)  
PRAI US 2000-198086P 20000417 (60)  
DT Utility  
FS APPLICATION

LN.CNT 1794  
INCL INCLM: 424/472.000  
INCLS: 514/215.000  
NCL NCLM: 424/472.000  
NCLS: 514/215.000  
IC [7]  
ICM: A61K009-24  
ICS: A61K031-55

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 29 USPATFULL on STN  
AN 2002:37338 USPATFULL  
TI Drug delivery system for averting pharmacokinetic drug interaction and method thereof  
IN Sawada, Toyohiro, Fujieda-shi, JAPAN  
Sako, Kazuhiro, Yaizu-shi, JAPAN  
Yoshioka, Tatsunobu, Yaizu-shi, JAPAN  
Watanable, Shunsuke, Fujieda-shi, JAPAN  
PI US 2002022054 A1 20020221  
AI US 2001-834414 A1 20010412 (9)  
PRAI US 2000-197574P 20000417 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 1496  
INCL INCLM: 424/468.000  
INCLS: 514/171.000; 514/304.000; 514/284.000  
NCL NCLM: 424/468.000  
NCLS: 514/171.000; 514/304.000; 514/284.000  
IC [7]  
ICM: A61K009-22  
ICS: A61K031-56

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 29 USPATFULL on STN  
AN 2001:131297 USPATFULL  
TI Preparation for the treatment of metabolic syndrome containing human growth hormone in combination with a cortisol synthesis inhibitor  
IN M.ang.rin, Per, Goteborg, Sweden  
PA Cortendo AB, Vastra Frolunda, Sweden (non-U.S. corporation)  
PI US 6274582 B1 20010814  
AI US 1999-379832 19990824 (9)  
RLI Continuation of Ser. No. WO 1998-GB574, filed on 24 Feb 1998  
PRAI SE 1997-642 19970224  
DT Utility  
FS GRANTED  
LN.CNT 437  
INCL INCLM: 514/254.100  
INCLS: 514/399.000; 514/012.000; 514/178.000; 514/179.000  
NCL NCLM: 514/254.100  
NCLS: 514/012.000; 514/178.000; 514/179.000; 514/399.000  
IC [7]  
ICM: A61K031-495  
ICS: A61K031-415; A61K038-00  
EXF 514/12; 514/178; 514/179; 514/254.1; 514/399  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 29 USPATFULL on STN  
AN 2001:10889 USPATFULL  
TI Treatment of glaucoma and ocular hypertension  
IN Clark, Abbot F., Arlington, TX, United States  
Conrow, Raymond E., Fort Worth, TX, United States  
PA Alcon Laboratories, Inc., Fort Worth, TX, United States (U.S. corporation)

PI US 6177427 B1 20010123  
AI US 1999-346424 19990701 (9)  
RLI Continuation of Ser. No. US 1997-858298, filed on 19 May 1997, now abandoned Continuation of Ser. No. US 1996-631041, filed on 12 Apr 1996, now abandoned Continuation of Ser. No. US 1994-268086, filed on 28 Jun 1994, now abandoned  
DT Utility  
FS Granted  
LN.CNT 473  
INCL INCLM: 514/239.200  
INCLS: 514/255.000; 514/383.000; 514/396.000; 514/406.000; 544/177.000;  
544/396.000; 548/262.200; 548/373.100; 548/572.000  
NCL NCLM: 514/239.200  
NCLS: 514/255.040; 514/383.000; 514/396.000; 514/406.000; 544/177.000;  
544/396.000; 548/262.200; 548/373.100; 548/572.000  
IC [7]  
ICM: A61K031-415  
ICS: C07D231-10; C07D207-04; C07D265-30  
EXF 514/396; 514/397; 514/239.2; 514/255; 514/406; 514/383; 548/346.1;  
548/314.7; 548/262.2; 548/572; 548/373.1; 544/177; 544/396  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 29 USPATFULL on STN  
AN 2001:4475 USPATFULL  
TI Methods for releasing a ligand from a complex  
IN Staples, Mark A., San Jose, CA, United States  
Haley, Carolyn J., Morgan Hill, CA, United States  
Parrish, Richard F., San Jose, CA, United States  
Zmolek, Wesley W., Freemont, CA, United States  
PA Dade Behring Marburg GmbH, Marburg, Germany, Federal Republic of  
(non-U.S. corporation)  
PI US 6171801 B1 20010109  
AI US 1997-896244 19970717 (8)  
PRAI US 1996-22133P 19960718 (60)  
DT Patent  
FS Granted  
LN.CNT 1370  
INCL INCLM: 435/007.100  
INCLS: 435/007.900; 435/961.000; 435/962.000; 436/177.000; 436/174.000;  
436/536.000; 436/825.000  
NCL NCLM: 435/007.100  
NCLS: 435/007.900; 435/961.000; 435/962.000; 436/174.000; 436/177.000;  
436/536.000; 436/825.000  
IC [7]  
ICM: G01N033-53  
ICS: G01N033-531; G01N001-18; G01N001-00  
EXF 435/7.9; 435/7.1; 435/962; 435/961; 436/501; 436/174; 436/825; 436/177;  
436/536  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 29 USPATFULL on STN  
AN 2000:174644 USPATFULL  
TI Method of using ketoconazole and related substances in medicaments for  
treatment of type II diabetes and methods of treating same  
IN Marin, Per, Goteborg, Sweden  
PA Cortendo, AB, Gothenburg, Sweden (non-U.S. corporation)  
PI US 6166017 20001226  
AI US 1998-211282 19981214 (9)  
RLI Continuation of Ser. No. US 776983  
DT Utility  
FS Granted  
LN.CNT 238  
INCL INCLM: 514/247.000  
INCLS: 514/178.000; 514/396.000; 514/467.000; 514/866.000

NCL NCLM: 514/247.000  
NCLS: 514/178.000; 514/396.000; 514/467.000; 514/866.000  
IC [7]  
ICM: A61K031-50  
ICS: A61K031-56; A61K031-415; A61K031-335  
EXF 514/247; 514/178; 514/396; 514/467; 514/866  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 29 USPATFULL on STN  
AN 2000:47230 USPATFULL  
TI Treatment of GLC1A glaucoma with non-steroidal glucocorticoid  
antagonists  
IN Clark, Abbot F., Arlington, TX, United States  
PA Alcon Laboratories, Inc., Fort Worth, TX, United States (U.S.  
corporation)  
PI US 6051573 20000418  
AI US 1997-994957 19971219 (8)  
RLI Continuation-in-part of Ser. No. US 1997-858298, filed on 19 May 1997,  
now abandoned which is a continuation-in-part of Ser. No. US  
1996-631041, filed on 12 Apr 1996, now abandoned which is a continuation  
of Ser. No. US 1994-268086, filed on 28 Jun 1994, now abandoned  
DT Utility  
FS Granted  
LN.CNT 638  
INCL INCLM: 514/235.500  
INCLS: 514/239.200; 514/255.000; 514/333.000; 514/340.000; 514/341.000;  
514/343.000; 514/359.000; 514/424.000; 514/425.000; 514/427.000;  
514/428.000; 514/408.000  
NCL NCLM: 514/235.500  
NCLS: 514/239.200; 514/252.100; 514/252.110; 514/253.090; 514/255.050;  
514/333.000; 514/340.000; 514/341.000; 514/343.000; 514/359.000;  
514/408.000; 514/424.000; 514/425.000; 514/427.000; 514/428.000  
IC [7]  
ICM: A61K031-535  
ICS: A01N043-60; A01N043-40; A01N043-64; A01N043-36  
EXF 514/235.5; 514/239.2; 514/255; 514/333; 514/340; 514/341; 514/343;  
514/359; 514/424; 514/425; 514/427; 514/428; 514/408  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 29 USPATFULL on STN  
AN 1999:19138 USPATFULL  
TI Low dosage treatment for cocaine craving and withdrawal  
IN Goeders, Nicholas E., Shreveport, LA, United States  
PA Board of Supervisors of Louisiana State University and Agricultural and  
Mechanical College, Baton Rouge, LA, United States (U.S. corporation)  
PI US 5869474 19990209  
AI US 1997-857376 19970516 (8)  
DT Utility  
FS Granted  
LN.CNT 732  
INCL INCLM: 514/171.000  
INCLS: 514/252.000; 514/327.000; 514/382.000; 514/396.000; 514/812.000  
NCL NCLM: 514/171.000  
NCLS: 514/254.070; 514/327.000; 514/382.000; 514/396.000; 514/812.000  
IC [6]  
ICM: A61K031-50  
ICS: A61K031-56; A61K031-495  
EXF 514/171; 514/252; 514/327; 514/382; 514/396; 514/812  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 29 USPATFULL on STN  
AN 1998:157342 USPATFULL  
TI Methods for using ketoconazole and related substances in medicaments for  
treatment of type II diabetes

IN Marin, Per, Goteborg, Sweden  
PA Cortendo AB, Gothenburg, Sweden (non-U.S. corporation)  
PI US 5849740 19981215  
WO 9604912 19960222  
AI US 1997-776983 19970206 (8)  
WO 1994-SE729 19940809  
19970206 PCT 371 date  
19970206 PCT 102(e) date  
DT Utility  
FS Granted  
LN.CNT 174  
INCL INCLM: 514/247.000  
INCLS: 514/178.000; 514/396.000; 514/467.000; 514/866.000  
NCL NCLM: 514/247.000  
NCLS: 514/178.000; 514/396.000; 514/467.000; 514/866.000  
IC [6]  
ICM: A61K031-50  
ICS: A61K031-56; A61K031-415; A61K031-335  
EXF 514/247; 514/396; 514/467; 514/866; 514/178  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
  
L8 ANSWER 17 OF 29 USPATFULL on STN  
AN 1998:33606 USPATFULL  
TI Gas and gaseous precursor filled microspheres as topical and  
subcutaneous delivery vehicles  
IN Unger, Evan C., Tucson, AZ, United States  
Matsunaga, Terry O., Tucson, AZ, United States  
Yellowhair, David, Tucson, AZ, United States  
PA ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)  
PI US 5733572 19980331  
AI US 1994-346426 19941129 (8)  
RLI Continuation-in-part of Ser. No. US 1994-307305, filed on 16 Sep 1994  
Ser. No. Ser. No. US 1993-159687, filed on 30 Nov 1993, now patented,  
Pat. No. US 5585112 Ser. No. Ser. No. US 1993-160232, filed on 30 Nov  
1993, now patented, Pat. No. US 5542935 And Ser. No. US 1993-159674,  
filed on 30 Nov 1993, now abandoned, said Ser. No. US -159687 Ser.  
No. Ser. No. US -160232 And Ser. No. US -159674, each Ser. No. US  
- which is a continuation-in-part of Ser. No. US 1993-76239, filed on 11  
Jun 1993, now patented, Pat. No. US 5469854 And Ser. No. US 1993-76250,  
filed on 11 Jun 1993, now patented, Pat. No. US 5580575, said Ser. No.  
US -76239 And Ser. No. US -76250, each Ser. No. US - which is a  
continuation-in-part of Ser. No. US 1991-717084, filed on 18 Jun 1991,  
now patented, Pat. No. US 5228446 And Ser. No. US 1991-716899, filed on  
18 Jun 1991, now abandoned, said Ser. No. US -717084 And Ser. No. US  
-716899, each Ser. No. US - which is a continuation-in-part of Ser.  
No. US 1990-569828, filed on 20 Aug 1990, now patented, Pat. No. US  
5088499 which is a continuation-in-part of Ser. No. US 1989-455707,  
filed on 22 Dec 1989, now abandoned  
DT Utility  
FS Granted  
LN.CNT 4174  
INCL INCLM: 424/450.000  
INCLS: 424/121.000; 424/009.321; 424/009.400; 424/489.000; 436/829.000  
NCL NCLM: 424/450.000  
NCLS: 424/001.210; 424/009.321; 424/009.400; 424/489.000; 436/829.000  
IC [6]  
ICM: A61K009-127  
EXF 424/450; 424/1.21; 424/9.321; 424/9.4; 424/489; 436/829  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
  
L8 ANSWER 18 OF 29 USPATFULL on STN  
AN 97:73588 USPATFULL  
TI Method for topical inhibition of the metabolic activity of cytochrome  
P450

IN Gelland, Yuri, Pittsburgh, PA, United States  
Wolf, Bruce L., Nashville, TN, United States  
PA TWK, Inc., Nashville, TN, United States (U.S. corporation)  
PI US 5658881 19970819  
AI US 1994-323267 19941014 (8)  
DT Utility  
FS Granted  
LN.CNT 352  
INCL INCLM: 514/011.000  
INCLS: 514/171.000; 514/252.000; 514/399.000  
NCL NCLM: 514/011.000  
NCLS: 514/171.000; 514/254.070; 514/399.000  
IC [6]  
ICM: A61K031-57  
ICS: A61K031-415; A61K031-495; A61K038-13  
EXF 514/171; 514/252; 514/399; 514/11  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 29 USPATFULL on STN  
AN 96:77760 USPATFULL  
TI Combination therapy for the treatment of estrogen-sensitive disease  
IN Labrie, Fernand, Quebec, Canada  
PA Endorecherche Inc., Quebec, Canada (non-U.S. corporation)  
PI US 5550107 19960827  
AI US 1991-785890 19911104 (7)  
RLI Continuation of Ser. No. US 1989-321926, filed on 10 Mar 1989, now  
abandoned  
DT Utility  
FS Granted  
LN.CNT 1665  
INCL INCLM: 514/011.000  
INCLS: 514/015.000; 514/169.000; 514/170.000; 514/161.000; 514/255.000;  
514/328.000; 514/649.000; 514/617.000  
NCL NCLM: 514/011.000  
NCLS: 514/015.000; 514/169.000; 514/170.000; 514/171.000; 514/250.000;  
514/328.000; 514/617.000; 514/649.000  
IC [6]  
ICM: A61K038-00  
ICS: A61K031-56; A61K031-495; A61K031-50; A61K031-445; A61K031-165;  
A61K031-135  
EXF 514/11; 514/15; 514/169; 514/170; 514/171; 514/255; 514/328; 514/617;  
514/649  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 29 USPATFULL on STN  
AN 95:62727 USPATFULL  
TI Method of retarding the progression of chronic renal failure  
IN Walser, Mackenzie, Ruxton, MD, United States  
PA The John Hopkins University, Baltimore, MD, United States (U.S.  
corporation)  
PI US 5432176 19950711  
AI US 1992-996757 19921224 (7)  
RLI Continuation-in-part of Ser. No. US 1988-277161, filed on 29 Nov 1988,  
now patented, Pat. No. US 5175144  
DT Utility  
FS Granted  
LN.CNT 471  
INCL INCLM: 514/252.000  
INCLS: 514/002.000; 514/011.000; 514/171.000; 514/289.000; 514/327.000  
NCL NCLM: 514/254.070  
NCLS: 514/002.000; 514/011.000; 514/171.000; 514/289.000; 514/327.000  
IC [6]  
ICM: A61K031-495  
ICS: A61K031-50; A61K037-00; A61K031-56

EXF 514/2; 514/11; 514/179; 514/252; 514/282; 514/289; 514/327; 514/171  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 29 USPATFULL on STN  
AN 92:106806 USPATFULL  
TI Method of retarding the progression of chronic renal failure  
IN Walser, Mackenzie, Ruxton, MD, United States  
PA The Johns Hopkins University, Baltimore, MD, United States (U.S.  
corporation)  
PI US 5175144 19921229  
AI US 1988-277161 19881129 (7)  
DT Utility  
FS Granted  
LN.CNT 476  
INCL INCLM: 514/002.000  
INCLS: 514/011.000; 514/179.000; 514/252.000; 514/282.000; 514/289.000;  
514/327.000  
NCL NCLM: 514/002.000  
NCLS: 514/011.000; 514/179.000; 514/254.070; 514/282.000; 514/289.000;  
514/327.000  
IC [5]  
ICM: A61K037-00  
ICS: A61K031-56; A61K021-495; A61K031-50; A61K031-44; A61K031-445  
EXF 514/179; 514/2; 514/11; 514/252; 514/282; 514/289; 514/327  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 29 USPATFULL on STN  
AN 91:92512 USPATFULL  
TI Combination therapy for selected sex steroid dependent cancers  
IN Labrie, Fernand, 2735 Boul. Ilgeois, Ste-Foy, Quebec, Canada G1W 1Z9  
PI US 5064813 19911112  
AI US 1989-413613 19891109 (7)  
RLI Continuation of Ser. No. US 1988-146597, filed on 21 Jan 1988, now  
abandoned which is a continuation of Ser. No. US 1986-892214, filed on  
31 Jul 1986, now patented, Pat. No. US 4760053  
DT Utility  
FS Granted  
LN.CNT 952  
INCL INCLM: 514/015.000  
INCLS: 514/177.000; 514/178.000; 514/358.000; 514/800.000  
NCL NCLM: 514/015.000  
NCLS: 514/128.000; 514/177.000; 514/358.000; 514/800.000  
IC [5]  
ICM: A61K037-02  
EXF 514/15; 514/177; 514/178; 514/358; 514/800  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 29 USPATFULL on STN  
AN 91:46693 USPATFULL  
TI Combination male breast cancer therapy  
IN Labrie, Fernand, 2735 boul Liegeois, St-Foy, Quebec, Canada G1W 1Z9  
PI US 5023234 19910611  
AI US 1985-699710 19850208 (6)  
DT Utility  
FS Granted  
LN.CNT 572  
INCL INCLM: 514/015.000  
INCLS: 514/392.000; 514/649.000  
NCL NCLM: 514/015.000  
NCLS: 514/392.000; 514/649.000  
IC [5]  
ICM: A61K037-02  
ICS: C07K007-06  
EXF 514/15

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 24 OF 29 USPATFULL on STN  
AN 89:92340 USPATFULL  
TI Lipid nano-pellets as excipient system for perorally administered drugs  
IN Speiser, Peter, Zurich, Switzerland  
PA Dr. Rentschler Arzneimittel GmbH & Co., Laupheim, Germany, Federal  
Republic of (non-U.S. corporation)  
PI US 4880634 19891114  
AI US 1987-66459 19870626 (7)  
RLI Continuation of Ser. No. US 1985-740771, filed on 30 Jun 1985, now  
abandoned  
PRAI DE 1984-3421468 19840608  
DT Utility  
FS Granted  
LN.CNT 820  
INCL INCLM: 424/450.000  
INCLS: 424/502.000; 514/786.000  
NCL NCLM: 424/450.000  
NCLS: 424/502.000; 514/786.000  
IC [4]  
ICM: A61K037-22  
ICS: A61K009-50; A61K047-00  
EXF 514/786; 514/943; 514/938; 514/937; 514/964; 424/502; 424/450  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 25 OF 29 USPATFULL on STN  
AN 89:21171 USPATFULL  
TI Method for treatment of hypercortisolemic, depressed patients  
IN Ravaris, Charles L., Hanover, NH, United States  
PA The Trustees of Dartmouth College, Hanover, NH, United States (U.S.  
corporation)  
PI US 4814333 19890321  
AI US 1988-154338 19880210 (7)  
RLI Continuation-in-part of Ser. No. US 1987-78814, filed on 28 Jul 1987,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 360  
INCL INCLM: 514/255.000  
NCL NCLM: 514/254.070  
IC [4]  
ICM: A61K031-495  
EXF 514/255  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 26 OF 29 USPATFULL on STN  
AN 88:64035 USPATFULL  
TI Combination therapy for treatment of female breast cancer  
IN Labrie, Fernand, 2735 boul Liegeois, St-Foy, Quebec, G1W 1Z9, Canada  
PI US 4775661 19881004  
AI US 1987-47830 19870506 (7)  
RLI Division of Ser. No. US 1985-699702, filed on 8 Feb 1985, now patented,  
Pat. No. US 4666885  
DT Utility  
FS Granted  
LN.CNT 498  
INCL INCLM: 514/015.000  
INCLS: 514/800.000; 206/219.000  
NCL NCLM: 514/015.000  
NCLS: 206/219.000; 514/800.000; 930/020.000; 930/021.000; 930/130.000  
IC [4]  
ICM: A61K037-24  
ICS: B65D077-04

EXF 206/219; 514/15; 514/800  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 27 OF 29 USPATFULL on STN  
AN 88:47260 USPATFULL  
TI Combination therapy for selected sex steroid dependent cancers  
IN Labrie, Fernand, 2735 boul. Liegeois, Ste-Foy, Quebec, Canada G1W 1Z9  
PI US 4760053 19880726  
AI US 1986-892214 19860731 (6)  
PRAI WO 1985-US1454 19850802  
DT Utility  
FS Granted  
LN.CNT 1029  
INCL INCLM: 514/015.000  
INCLS: 514/177.000; 514/178.000; 514/800.000; 514/358.000  
NCL NCLM: 514/015.000  
NCLS: 514/177.000; 514/178.000; 514/358.000; 514/800.000; 930/010.000;  
930/020.000; 930/021.000; 930/130.000  
IC [4]  
ICM: A61K037-43  
EXF 530/328; 530/313; 514/178; 514/800; 514/177; 514/358; 514/15  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 28 OF 29 USPATFULL on STN  
AN 87:36065 USPATFULL  
TI Combination therapy for treatment of female breast cancer  
IN Labrie, Fernand, 2735 boul Liegeois, St-Foy, Quebec, G1W 1Z9, Canada  
PI US 4666885 19870519  
AI US 1985-699702 19850208 (6)  
DT Utility  
FS Granted  
LN.CNT 656  
INCL INCLM: 514/015.000  
NCL NCLM: 514/015.000  
NCLS: 930/020.000; 930/021.000; 930/130.000  
IC [4]  
ICM: A61K037-24  
EXF 260/112.5R; 514/15  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 29 OF 29 USPATFULL on STN  
AN 87:28333 USPATFULL  
TI Method of treatment of prostate cancer  
IN Labrie, Fernand, 2735 boul Liegeois, St-Foy, Quebec, G1W 1Z9, Canada  
PI US 4659695 19870421  
AI US 1985-699711 19850208 (6)  
DT Utility  
FS Granted  
LN.CNT 604  
INCL INCLM: 514/015.000  
INCLS: 514/800.000  
NCL NCLM: 514/015.000  
NCLS: 514/800.000  
IC [4]  
ICM: A61K037-24  
EXF 514/15; 514/800  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 28 hit

L8 ANSWER 28 OF 29 USPATFULL on STN  
DETD When an inhibitor of adrenal sex steroid biosynthesis, e.g.,  
aminoglutethimide is administered, cortisol biosynthesis is

blocked. Accordingly, hydrocortisone is administered in physiological amounts sufficient to maintain normal glucocorticoid levels.

IT 50-23-7 125-84-8 13311-84-7 65277-42-1  
(neoplasm inhibition with antiandrogens and antiestrogens and)

=> d 21 hit

L8 ANSWER 21 OF 29 USPATFULL on STN

DETD Glucocorticoids are corticosteroids predominantly affecting carbohydrate metabolism. Endogenous glucocorticoids influence fat and protein metabolism and have many other activities, such as affecting muscle tone and the excitation of nerve tissue and the microcirculation. In humans, the most important glucocorticoid is **cortisol** (hydrocortisone).

DETD (1) Sodium valproate: This is an anticonvulsant, widely used, but not without serious side effects and toxicity. It has recently been shown to reduce serum **cortisol** levels by more than fifty percent within a few hours in normal subjects. Aggernaes, H. et al., "The Effect of Sodium Valproate on Serum Cortisol Levels in Healthy Subjects and Depressed Patients," *Acta Psychiatr. Scand.*, 77:170-174 (1988).

DETD (2) Enkephalins: These pentapeptides and their synthetic analogs, notably "DAMME" ([D-ala.<sup>2</sup>, MePhe.<sup>4</sup>, Met(O)-ol] enkephalin), reduce **cortisol** levels acutely in man. Stubbs, W. A., et al., "Hormonal and Metabolic Responses to an Enkephalin Analog in Normal Man", *The Lancet*, 1978:1225-1227 (Dec. 9, 1978); and Taylor, T., "Beta-Endorphin Suppresses Adrenocorticotropin and **Cortisol** Levels in Normal Human Subjects," *Journal of Clinical Endocrinology and Metabolism*, 57:592-596 (1983).

DETD (3) Opioids: Alkaloids like morphine also interact with the same or similar receptors as enkephalins. Opioids shown to decrease **cortisol** levels in man include morphine, pentazocine, nalorphine and buprenorphine. Pende, A., et al., "Evaluation of the Effects Induced by Four Opiate Drugs, with Different Affinity to Opioid Receptor Subtypes, on Interior Pituitary LH, TSH, PRL and GH Secretion and on **Cortisol** Secretion in Normal Man," *Biomed Pharmacother*, 40:178-82 (1986). Chronic administration of these may not be practical owing to side effects and/or addictive properties. However, loperamide, commercially available under the trademark "IMODIUM" from Janssen Pharmaceutica, N. V., is not addictive, but does suppress adrenocorticotrophic hormone production. See Ambrosi, B., et al., "Loperamide, an Opiate Analog, Inhibits Plasma ACTH Levels in Patients with Addison's Disease," *Clinical Endocrinology*, 24:483-489 (1986). Loperamine and similar butyramides are described in U.S. Pat. No. 3,714,159 of Janssen, et al.

DETD (4) Clonidine: This widely used antihypertensive drug has recently been shown to lower **cortisol** levels in man. See Slowinska-Szednicka, J., et al., "Effect of Clonidine on Beta-Endorphin, ACTH and **Cortisol** Secretion in Essential Hypertension and Obesity," *European Journal of Clinical Pharmacology*, 35:115-121 (1988); and Lechin, F., et al. "Role of Stress in the Exacerbation of Chronic Illness: Effects of Clonidine Administration on Blood Pressure and Plasma Norepinephrine, **Cortisol**, Growth Hormone and Prolactin Concentrations," *Psychoneuroendocrinology*, 12:117-129 (1987). Clonidine is already commonly used to treat hypertension in patients with chronic renal failure.

DETD (5) Ketoconazole: This is an antifungal agent found to inhibit adrenocortical glucocorticoid production profoundly or even completely. Farwell, A. P., et al., "Total Suppression of **Cortisol** Excretion by Ketoconazole in the Therapy of the Ectopic Adrenocorticotrophic Hormone Syndrome," *The American Journal of Medicine*, 84:1063-1066 (1988). However, ketoconazole is quite toxic.

DETD (6) Oxytocin: Intravenous infusion of this hormone (widely used to induce labor) lowers **cortisol** levels in normal men. Legros, J.

J., et al. "Confirmation of the Inhibitory Influence of Exogenous Oxytocin on Cortisol and ACTH in Man: Evidence of Reproducability," ACTA Endocrinologica, 114:345-349 (1987). Oxytocin can be given as an intranasal spray, and side effects are minor.

IT 50-56-6, Oxytocin, biological studies 57-27-2, Morphine, biological studies 561-27-3, Heroin 1069-66-5, Sodium valproate 64854-64-4, DAMME 65277-42-1, Ketoconazole 84371-65-3, Mifepristone (chronic renal failure progression retardation with, as agent suppressing glucocorticoids prodn., in human)

=> s 18 and (heart or cardiac)

95773 HEART

42578 CARDIAC

L9 5 L8 AND (HEART OR CARDIAC)

=> d 19 1-5

L9 ANSWER 1 OF 5 USPATFULL on STN

AN 2003:188461 USPATFULL

TI Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes

IN Marfat, Anthony, UNITED STATES

McKechney, Michael William, UNITED STATES

PI US 2003130254 A1 20030710

AI US 2002-300959 A1 20021120 (10)

RLI Division of Ser. No. US 2002-62145, filed on 31 Jan 2002, PENDING

PRAI US 2001-265486P 20010131 (60)

DT Utility

FS APPLICATION

LN.CNT 7168

INCL INCLM: 514/210.200

INCLS: 514/227.800; 514/235.500; 514/249.000; 514/248.000; 514/263.200;  
514/266.200; 514/256.000; 514/255.050; 514/252.050; 514/365.000;  
514/314.000

NCL NCLM: 514/210.200

NCLS: 514/227.800; 514/235.500; 514/249.000; 514/248.000; 514/263.200;  
514/266.200; 514/256.000; 514/255.050; 514/252.050; 514/365.000;  
514/314.000

IC [7]

ICM: A61K031-541

ICS: A61K031-5377; A61K031-506; A61K031-52; A61K031-517; A61K031-4709;  
A61K031-427; C07D417-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 5 USPATFULL on STN

AN 2002:338241 USPATFULL

TI Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes

IN Chambers, Robert J., Mystic, CT, UNITED STATES

Marfat, Anthony, Mystic, CT, UNITED STATES

Magee, Thomas V., Mystic, CT, UNITED STATES

PA Pfizer Inc. (U.S. corporation)

PI US 2002193612 A1 20021219

AI US 2002-62813 A1 20020131 (10)

PRAI US 2001-265492P 20010131 (60)

DT Utility

FS APPLICATION

LN.CNT 7001

INCL INCLM: 549/200.000

NCL NCLM: 549/200.000

IC [7]

ICM: C07D321-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 5 USPATFULL on STN

AN 2002:228358 USPATFULL  
TI Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes  
IN Marfat, Anthony, Mystic, CT, UNITED STATES  
McKechney, Michael William, Fairport, NY, UNITED STATES  
PA Pfizer Inc. (U.S. corporation)  
PI US 2002123520 A1 20020905  
US 6559168 B2 20030506  
AI US 2002-62145 A1 20020131 (10)  
PRAI US 2001-265486P 20010131 (60)  
DT Utility  
FS APPLICATION  
LN.CNT 6963  
INCL INCLM: 514/365.000  
INCLS: 514/398.000; 548/188.000; 548/323.100; 514/341.000; 514/342.000;  
546/269.700; 546/272.700  
NCL NCLM: 514/338.000  
NCLS: 514/342.000; 514/369.000; 514/370.000; 546/269.700; 548/188.000;  
548/195.000; 548/196.000  
IC [7]  
ICM: A61K031-4439  
ICS: A61K031-426; C07D417-02; C07D043-02  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 5 USPATFULL on STN  
AN 1998:33606 USPATFULL  
TI Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles  
IN Unger, Evan C., Tucson, AZ, United States  
Matsunaga, Terry O., Tucson, AZ, United States  
Yellowhair, David, Tucson, AZ, United States  
PA ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)  
PI US 5733572 19980331  
AI US 1994-346426 19941129 (8)  
RLI Continuation-in-part of Ser. No. US 1994-307305, filed on 16 Sep 1994  
Ser. No. Ser. No. US 1993-159687, filed on 30 Nov 1993, now patented,  
Pat. No. US 5585112 Ser. No. Ser. No. US 1993-160232, filed on 30 Nov  
1993, now patented, Pat. No. US 5542935 And Ser. No. US 1993-159674,  
filed on 30 Nov 1993, now abandoned, said Ser. No. US -159687 Ser.  
No. Ser. No. US -160232 And Ser. No. US -159674, each Ser. No. US  
- which is a continuation-in-part of Ser. No. US 1993-76239, filed on 11  
Jun 1993, now patented, Pat. No. US 5469854 And Ser. No. US 1993-76250,  
filed on 11 Jun 1993, now patented, Pat. No. US 5580575, said Ser. No.  
US -76239 And Ser. No. US -76250, each Ser. No. US - which is a  
continuation-in-part of Ser. No. US 1991-717084, filed on 18 Jun 1991,  
now patented, Pat. No. US 5228446 And Ser. No. US 1991-716899, filed on  
18 Jun 1991, now abandoned, said Ser. No. US -717084 And Ser. No. US  
-716899, each Ser. No. US - which is a continuation-in-part of Ser.  
No. US 1990-569828, filed on 20 Aug 1990, now patented, Pat. No. US  
5088499 which is a continuation-in-part of Ser. No. US 1989-455707,  
filed on 22 Dec 1989, now abandoned  
DT Utility  
FS Granted  
LN.CNT 4174  
INCL INCLM: 424/450.000  
INCLS: 424/121.000; 424/009.321; 424/009.400; 424/489.000; 436/829.000  
NCL NCLM: 424/450.000  
NCLS: 424/001.210; 424/009.321; 424/009.400; 424/489.000; 436/829.000  
IC [6]  
ICM: A61K009-127  
EXF 424/450; 424/1.21; 424/9.321; 424/9.4; 424/489; 436/829  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 5 USPATFULL on STN

AN 89:92340 USPATFULL  
TI Lipid nano-pellets as excipient system for perorally administered drugs  
IN Speiser, Peter, Zurich, Switzerland  
PA Dr. Rentschler Arzneimittel GmbH & Co., Laupheim, Germany, Federal  
Republic of (non-U.S. corporation)  
PI US 4880634 19891114  
AI US 1987-66459 19870626 (7)  
RLI Continuation of Ser. No. US 1985-740771, filed on 30 Jun 1985, now  
abandoned  
PRAI DE 1984-3421468 19840608  
DT Utility  
FS Granted  
LN.CNT 820  
INCL INCLM: 424/450.000  
INCLS: 424/502.000; 514/786.000  
NCL NCLM: 424/450.000  
NCLS: 424/502.000; 514/786.000  
IC [4]  
ICM: A61K037-22  
ICS: A61K009-50; A61K047-00  
EXF 514/786; 514/943; 514/938; 514/937; 514/964; 424/502; 424/450  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

RN 65277-42-1 REGISTRY  
CN Piperazine, 1-acetyl-4-[4-[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl-, rel- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Piperazine, 1-acetyl-4-[4-[(2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl-, cis-

OTHER NAMES:

CN (+)-Ketoconazole

CN Fungarest

CN Fungoral

CN Ketoconazole

CN Ketoderm

CN Ketoisdin

CN Nizoral

CN Nizral

CN Orifungal M

CN Panfugol

CN R 41400

FS STEREOSEARCH

DR 72093-26-6

MF C26 H28 Cl2 N4 O4

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS\*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Relative stereochemistry.

